Nanobiotix S.A.

ENXTPA:NANO Stock Report

Market Cap: €1.6b

Nanobiotix Future Growth

Future criteria checks 5/6

Nanobiotix is forecast to grow earnings and revenue by 55.6% and 20.9% per annum respectively while EPS is expected to grow by 55.7% per annum.

Key information

55.6%

Earnings growth rate

55.68%

EPS growth rate

Biotechs earnings growth58.3%
Revenue growth rate20.9%
Future return on equityn/a
Analyst coverage

Good

Last updated03 Jun 2026

Recent future growth updates

Recent updates

New Narrative • Apr 30

Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential

Catalysts About Nanobiotix Nanobiotix develops nanoparticle based drug candidates intended to improve the effectiveness of existing cancer treatments such as radiotherapy and complex systemic therapies. What are the underlying business or industry changes driving this perspective?
New Narrative • Apr 16

Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment

Catalysts About Nanobiotix Nanobiotix develops nanotechnology based therapies designed to work alongside existing cancer treatments such as radiotherapy. What are the underlying business or industry changes driving this perspective?
New Narrative • Apr 01

Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech

Catalysts About Nanobiotix Nanobiotix is a biotechnology company focused on nanoscale therapies designed to work with existing treatments such as radiotherapy and complex biologic drugs. What are the underlying business or industry changes driving this perspective?
Analysis Article • Jan 31

New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)

Nanobiotix S.A. ( EPA:NANO ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Mar 14

Risks Still Elevated At These Prices As Nanobiotix S.A. (EPA:NANO) Shares Dive 27%

Nanobiotix S.A. ( EPA:NANO ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • Nov 28

Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%

To the annoyance of some shareholders, Nanobiotix S.A. ( EPA:NANO ) shares are down a considerable 26% in the last...
Analysis Article • Jun 29

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The Nanobiotix S.A. ( EPA:NANO ) share price has fared very poorly over the last month, falling by a substantial 27...
Analysis Article • May 14

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

Nanobiotix S.A. ( EPA:NANO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...
Analysis Article • Apr 26

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 11

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Dec 06

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Jun 04

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Dec 22

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

This article will reflect on the compensation paid to Laurent Levy who has served as CEO of Nanobiotix S.A. ( EPA:NANO...

Earnings and Revenue Growth Forecasts

ENXTPA:NANO - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028882977566
12/31/20275538-127
12/31/202644-10-30-237
12/31/202533-24-34-33N/A
9/30/202521-38-33-32N/A
6/30/202510-52-32-31N/A
3/31/20251-60-26-25N/A
12/31/2024-7-68-20-20N/A
9/30/202418-51-11-10N/A
6/30/202442-33-2-1N/A
3/31/202439-37-7-7N/A
12/31/202336-40-13-12N/A
9/30/202321-49-25-25N/A
6/30/20237-59-37-37N/A
3/31/20236-58-37-37N/A
12/31/20225-57-37-37N/A
9/30/20224-50-35-35N/A
6/30/20223-43-33-32N/A
3/31/20223-45-31-31N/A
12/31/20213-47-30-30N/A
9/30/20212-45-30-30N/A
6/30/20212-43-30-30N/A
3/31/20212-39-29-29N/A
12/31/20202-34-28-28N/A
9/30/20202-41-31-30N/A
6/30/20202-48-33-33N/A
3/31/20202-49-38-37N/A
12/31/20193-51-43-41N/A
9/30/20193-46N/A-37N/A
6/30/20193-42N/A-33N/A
3/31/20193-36N/A-30N/A
12/31/20183-30N/A-26N/A
9/30/20184-28N/A-24N/A
6/30/20184-27N/A-22N/A
3/31/20184-26N/A-22N/A
12/31/20174-26N/A-21N/A
9/30/20174-25N/A-20N/A
6/30/20174-24N/A-19N/A
3/31/20175-23N/A-19N/A
12/31/20165-22N/A-18N/A
9/30/20165-21N/A-19N/A
6/30/20165-19N/A-20N/A
3/31/20165-18N/A-19N/A
12/31/20154-17N/A-17N/A
9/30/20154-15N/A-15N/A
6/30/20153-13N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NANO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: NANO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NANO is expected to become profitable in the next 3 years.

Revenue vs Market: NANO's revenue (20.9% per year) is forecast to grow faster than the French market (5.7% per year).

High Growth Revenue: NANO's revenue (20.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NANO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 00:01
End of Day Share Price 2026/06/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nanobiotix S.A. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Philippa GardnerEdison Investment Research
Jonathan MillerEvercore ISI
Emmanuel ParotGilbert Dupont